Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

105.15EUR
11:35am EST
Change (% chg)

€0.45 (+0.43%)
Prev Close
€104.70
Open
€104.90
Day's High
€105.55
Day's Low
€104.75
Volume
1,560,433
Avg. Vol
1,828,812
52-wk High
€123.90
52-wk Low
€94.02

Latest Key Developments (Source: Significant Developments)

ASML announces CFO Wolfgang Nickl to leave by end of April 2018‍
Tuesday, 12 Sep 2017 06:02am EDT 

Sept 12 (Reuters) - ASML HOLDING NV ::CFO WOLFGANG NICKL TO LEAVE ASML BY THE END OF APRIL 2018‍​.‍WOLFGANG NICKL WILL JOIN GERMAN LIFE SCIENCE COMPANY BAYER <<>> AS ITS NEW CFO.​.  Full Article

Bayer and Vanderbilt University Medical Center agree five-year research alliance
Monday, 11 Sep 2017 08:05am EDT 

Sept 11 (Reuters) - BAYER AG ::‍BAYER AND VANDERBILT UNIVERSITY MEDICAL CENTER COLLABORATE TO DEVELOP THERAPIES AGAINST KIDNEY DISEASES​.‍BAYER WILL HAVE AN OPTION FOR EXCLUSIVE USE OF COLLABORATION RESULTS​.AGREED ON A FIVE-YEAR STRATEGIC RESEARCH ALLIANCE TO JOIN FORCES IN FIGHT AGAINST KIDNEY DISEASES.‍FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED​.  Full Article

Bayer submits U.S. license application for Hemophilia treatment
Thursday, 31 Aug 2017 12:35am EDT 

Aug 31 (Reuters) - Bayer AG :Says submits biologics license application in U.S. for BAY94-9027.  Full Article

Bayer says will continue to work with European Commission
Tuesday, 22 Aug 2017 09:03am EDT 

Aug 22 (Reuters) - Bayer Ag :‍confirmed that european commission has initiated a phase ii investigation of proposed combination of bayer and monsanto.says will continue to work constructively with the European Commission​.  Full Article

Bayer and SICIT 2000 sign exclusive distribution agreement‍​
Friday, 11 Aug 2017 08:43am EDT 

Aug 11 (Reuters) - BAYER AG :BAYER AND SICIT 2000 SIGN EXCLUSIVE DISTRIBUTION AGREEMENT‍​.FINANCIAL TERMS WERE NOT DISCLOSED‍​.UNDER THE AGREEMENT, BAYER WILL COMMERCIALIZE BAYFOLAN COBRE AND BAYFOLAN AKTIVATOR FOR FOLIAR USES IN VARIOUS CROPS WORLDWIDE.  Full Article

Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
Wednesday, 26 Jul 2017 07:09am EDT 

July 26 (Reuters) - Compugen Ltd ::Compugen discloses updates to collaborative activities with bayer in immuno-oncology.Compugen - agreement with Bayer AG involves research, development, commercialization of antibody-based therapeutics against cgen-15001t and cgen-15022.Compugen Ltd - it has been determined current collaboration will focus solely on cgen-15001t, all rights to cgen-15022 will be returned to Compugen.  Full Article

Bayer invests 92 million euros in Animal Health production
Monday, 3 Jul 2017 05:03am EDT 

July 3 (Reuters) - BAYER AG :INVESTS 92 MILLION EUROS IN ANIMAL HEALTH PRODUCTION.PROGRAM FOR EXPANDING SITE IN KIEL, GERMANY, UNTIL 2021.  Full Article

Monsanto reports Q3 earnings per share $1.90
Wednesday, 28 Jun 2017 08:00am EDT 

June 28 (Reuters) - Monsanto Co :Monsanto Company delivers solid third quarter as it looks to close out fiscal year 2017 with return to growth.Q3 earnings per share $1.93 from continuing operations.Q3 earnings per share $1.90.Q3 sales $4.23 billion versus I/B/E/S view $4.17 billion.Q3 earnings per share view $1.76 -- Thomson Reuters I/B/E/S.Monsanto Co - Expects full-year 2017 EPS at high end of range of $4.09 to $4.55 on an as-reported basis.Monsanto Co - Confirms EPS at high end of range of $4.50 to $4.90 on an ongoing basis for full-year 2017.Monsanto Co - Qtrly total seeds and genomics sales $3,132 million versus $3,207 million.Monsanto Co - Co ‍simultaneously working with Bayer toward completion of pending merger by end of calendar year​.Monsanto Co - Seed and genomics segment gross profit is now expected to be up high-single digits in terms of percentage for year.Monsanto Co - For agricultural productivity segment, gross profit is still expected to be in range of $850 to $950 million for 2017.Says ‍looking ahead to Q4, "company expects to receive benefit of about $70 million in non-core asset sale gains from strategic deals​".Monsanto Co - For full year, company still expects earnings to translate to high end of range of $1.2 billion to $1.6 billion of free cash flow.Monsanto - ‍Remains on-track with target of $380 million in savings by end of FY across cost of goods and operating expenses, as compared to FY 2015 base​.  Full Article

Bayer's Stivarga approved for hepatocellular carcinoma in Japan
Monday, 26 Jun 2017 03:00am EDT 

June 26 (Reuters) - Bayer AG :Says receives approval for Stivarga in Japan for second-line treatment of hepatocellular carcinoma.  Full Article

Bayer gets positive CHMP opinion for regorafenib
Friday, 23 Jun 2017 08:34am EDT 

June 23 (Reuters) - BAYER AG ::‍BAYER RECEIVES POSITIVE CHMP OPINION FOR REGORAFENIB FOR SECOND-LINE SYSTEMIC TREATMENT OF LIVER CANCER​.‍FINAL DECISION OF EUROPEAN COMMISSION ON MARKETING AUTHORIZATION IS EXPECTED IN COMING MONTHS​.  Full Article

BRIEF-Bayer's Rivaroxaban Submitted To U.S. FDA For Approval

* RIVAROXABAN SUBMITTED TO U.S. FDA FOR APPROVAL IN PATIENTS WITH CORONARY AND/OR PERIPHERAL ARTERY DISEASE Source text - http://bit.ly/2B4uKdl Further company coverage: (Gdynia Newsroom)